Reading the tape
NASDAQ: AKTS
Aktis Oncology, Inc.
Healthcare · Biotechnology
Market Cap
$1.03B
52w High
$29.16
52w Low
$14.72
P/E
-37.90
Volume
70.96K
Outstanding Shares
53.40M
Price vs Fundamentals
Why The Stock Is Moving
Likely multiple compressionModerate confidence
Note: The most recent financial data is over 3 months old. Metrics shown may not reflect the latest reporting period.
1Y Price: -14.77%Revenue (TTM): 100.43%FCF (TTM): -29.06%
What changed
The stock fell 14.77% over the last year. Revenue grew 100.43% over the trailing twelve months. Operating margin moved from -1,675.78% to -929.14%. Free cash flow declined 29.06% over the trailing twelve months.
What the market seems to be pricing
Visible fundamentals weakened far less than the stock price. The market appears to be discounting durability, risk, or trust rather than just the latest reported numbers.
What would invalidate this read
This read changes if operating margin (currently -929.14%) continues to decline, or if revenue growth turns negative. The bull case requires the business to hold its current trajectory.
Company profile
Aktis Oncology, Inc. operates as a clinical-stage oncology company that engages in the development of targeted radiopharmaceutical therapies for cancer treatment.
CEOMatthew Roden
SectorHealthcare
IndustryBiotechnology
Employees79
IPO dateJan 9, 2026
Valuation
Forward P/E—
EV/EBITDA-15.90
Enterprise value$1.15B
Stock splits
No stock splits recorded for this ticker.
Profitability & growth
Revenue growth—
Gross margin100%▲0.00%vs FY2024
Operating margin-1,177.67%▲67.16%vs FY2024
ROE43.61%▼12.94%vs FY2024
Analyst consensus
RatingBuy
Target price$30.50▲58.04%
4
Buy
3
Hold
0
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.
Next report
May 8, 2026
Q2 FY26 · EPS est -$0.33 · Revenue est $1.81M
View
Earnings history is still populating for this ticker.